combination, have been implicated in the pathogenesis of ASDs. [6] [7] [8] [9] [10] Mutations in many genes, including neuroligin-3 (NLGN3), neuroligin-4 (NLGN4), neurexin-1 (NRXN1), SH3 and multiple ankyrin repeat domains protein 2 (SHANK2), SH3 and multiple ankyrin repeat domains protein 3 (SHANK3), Parkinson protein 2 (PARK2), MACRO domain containing 2 (MACROD2), and semaphorin-5A (SEMA5A), have been associated with ASDs. 6, 7, 10 Epigenetic modifications also contribute to the etiology of ASDs.
For example, Wang et al. 11 reported that hypermethylation of the enolase 2 (ENO2) gene is present in 15% of patients with ASDs. It is noteworthy that microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), which play important roles as transcriptional and/or posttranscriptional regulators, [12] [13] [14] [15] [16] [17] [18] [19] [20] have also been implicated in ASDs and other neurological disorders. Some prominent functional studies have
shown that lncRNAs perform a wide variety of functions, including participating in the recruitment of chromatin modifying complexes, providing a scaffold for the assembly of protein complexes, modulating alternative splicing, and employing enhancer-like functions. 12, 21, 22 These diverse functions are essential components of both the normal physiological and developmental processes, as well as the etiology of many disorders and complex diseases. [23] [24] [25] Currently, full and systematic discussions of the relationship between lncRNAs and ASDs are highly limited. Therefore, this review summarizes the available information from previous outstanding publications with a focus on the contribution of lncRNAs to ASDs and to other genetic syndromes, such as FXS and RTT, which have a similar clinical presentation to ASDs.
| LNCRNAS AND THEIR MECHANISMS OF ACTION
LncRNAs, which are defined as untranslated RNA molecules greater than 200 nucleotides in length, can be derived from sense or antisense strands within protein-coding genes, intergenic regions, or pseudogenes. LncRNAs are spliced and processed so that they include a 5′-methyl-guanosine cap and 3′-poly (A) tail once transcribed.
LncRNAs can be localized to the nucleus or the cytoplasm, but many lncRNAs are expressed with temporal and tissue and/or cell specificity. 24 LncRNAs have a poorly conserved primary structure but relatively well-conserved secondary structure and splicing. 26, 27 The mechanisms of action of lncRNAs are diverse and not yet fully understand, but mainly include genetic imprinting, chromatin remodeling, cell cycle regulation, splicing regulation, mRNA degradation and translation regulation. 28, 29 LncRNAs have been shown to control every level of the regulation of the gene expression pathway. 24 An overview of the cellular functions of lncRNAs is shown in Figure 1 . This diverse set of functions and complex mechanisms further emphasizes the idea that lncRNAs are key components of numerous cellular processes.
Generally, lncRNAs regulate gene expression at three levels: transcriptional regulation, posttranscriptional regulation and epigenetic regulation.
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| LncRNAs regulate the transcription of other genes
Transcriptional regulation is the most vital regulation of gene expres- 
| LncRNAs regulate RNA processing and translation
LncRNAs play a role not only in transcriptional regulation but also in posttranscriptional regulation. They can regulate pre-mRNA splicing through the isolation of splicing factors or by regulating the distribution and phosphorylation of splicing factors in splicing speckles. 37, 38 Bernard et al. 39 showed that metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is highly expressed in neurons and impacts the expression of genes related to synaptogenesis by regulating the serine/arginine splicing factor. LncRNAs can also regulate RNA transfer, translation and degradation. In a typical example, the BACE1-antisense transcript (BACE-AS) is the natural antisense transcript of the β-site APP cleaving enzyme 1 gene (β-secretase 1, BACE1). BACE1 protein expression will increase if BACE1-AS binds to the BACE1 mRNA. The BACE1 protein can later cleave the β-amyloid peptide precursor to produce more β-amyloid peptide. 40 High levels of β-amyloid peptide plaques in the brain are a prominent feature of Alzheimer's disease. 41 Thus, BACE-AS participates in the pathological process of Alzheimer's disease. 
| LncRNAs participate in epigenetic regulation
Epigenetic regulation results in a change in gene expression without changing the nucleotide sequence of the gene. 
| LNCRNAS IN THE CENTRAL NERVOUS SYSTEM (CNS) AND BRAIN
The vertebrate CNS contains an enormous diversity of neuronal and glial cell types that differentiate and form networks through an intricate developmental program that must coordinate intrinsic and extrinsic stimuli to achieve proper form and function. 48 LncRNAs have been shown to be highly expressed within the central nervous system, particularly in the brain, where they sometimes exhibit specific spatiotemporal expression patterns. 49 Cells in the CNS show strong expression of lncRNAs, with 5458 of a total 9747 lncRNA transcripts detected in the human brain, including ~40% of the most highly and differentially expressed lncRNAs. 48, 50 These lncRNAs have been shown to be involved in several key aspects
The main regulatory mechanism of lncRNAs. This figure is referred to the figure in reference [133] 56, 57 Sox2 also plays key roles in adult neurogenesis. 58 Sox2DOT, an alternatively spliced isoform of Sox2OT, is also expressed in mouse brain and is enriched in areas associated with neurogenesis. 59 A recent study has revealed that the lncRNA rhabdomyosarcoma 2-associated transcript (RMST) physically interacts with Sox2 to coregulate a large pool of downstream genes implicated in neurogenesis.
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Formation of functional synapses is the fundamental process required for establishing neural circuits and ultimately for expressing complex behavior. This process is characterized by increased proliferation of neuronal cells and overproduction of synaptic connections. 61, 62 Aberrant regulation of synaptogenesis is more commonly seen than aberrant regulation of neurogenesis in many neurological disorders, such as ASDs and schizophrenia. 63 The lncRNA MALAT1, which has been reported to be enriched in neurons and nuclear speckles, regulates synaptic density and the expression levels of neuroligin 1 (NLGN1) and synaptic cell-adhesion molecule (SynCAM1) by regulation of serine/arginine-rich splicing factor. 38 The critical balance between excitation and inhibition in the brain is maintained by two major classes of neurons: excitatory projection neurons and inhibitory local circuit interneurons.
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GABA primarily mediates inhibition; thus, GABAergic interneuron function has been associated with many neurodevelopmental and neurodegenerative disorders such as ASDs, schizophrenia, and epilepsy. [65] [66] [67] Many lncRNAs, including Gtl2, Rian, Evf2, Copg2as, Dlx6-AS1 and others, have been reported to participate in the regulation of GABAergic interneuron functions. 68, 69 Evf2 is transcribed from the Dlx-5/6 ultraconserved region that recruits the transcription factors DLX and MECP2, which affect Dlx-5/6 enhancer activities via both cis-and trans-mechanisms. In an Evf2 mutant, the number of GABAergic interneurons in the dentate gyrus and hippocampus were reduced, resulting in synaptic inhibition.
is a key regulator of members of the DLX family of transcription factors that are involved in GABAergic neuronal differentiation.
Mariani and colleagues reported that DLX6-AS1 were upregulated in cerebral organoids derived from iPSCs made from patents with ASDs. 71 A recent study has also revealed that DLX6-AS1 upregulated in cerebral organoids derived from the autism gene CHD8 knockout iPSCs. were also differentially expressed.
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| LNCRNAS AND THE RISK OF ASDS
| LncRNAs and ASDs
73
To date, there have been two studies in which brain tissue from ASD subjects was assessed for changes in regulatory lncRNAs. 74, 75 Ziats and colleagues performed microarray profiling of over 33 000 annotated lncRNAs and 30 000 mRNA transcripts from postmortem prefrontal cortex and cerebellum tissue from autistic and control subjects. The data illustrated that 222 lncRNAs were differentially expressed between ASD cases and controls. Of those 222 lncRNAs, 82
and 143 were unique to the prefrontal cortex and the cerebellum, respectively. They also found that the number of lncRNAs differentially expressed within control brains was much greater than the number of lncRNAs differentially expressed within autistic brains (1375 lncRNAs vs 236 lncRNAs, respectively). 74 This finding is interesting in the context of imaging studies of autistic brains, which have indicated that there are fewer specialized regions in autistic brains than in the brains of healthy subjects. 76 The sample size in this study was small, giving it limited statistical power, but the exciting conclusion invites replication and expansion of these findings with a larger sample size. The other study, through postmortem genomewide transcriptome analysis to interrogate the lncRNA, splicing, and regional gene expression pattern in autism was conducted by Parikshak and colleagues. This high level of expression could decrease the production of MSN transcripts, the moesin level, and the number and length of the neuritis. 78 The genes DISC1 and ST7, along with their antisense transcripts DISC2 and ST7OT1-2, have also been linked with ASDs. 79, 80 These studies provide a new perspective on the identity and function of lncRNAs that are associated with ASDs.
| LncRNAs and Fragile X syndrome
Fragile X syndrome, a common cause of inherited intellectual disability and ASD, is inherited via an X-linked dominant mechanism and is characterized by moderate to severe mental retardation, macroorchidism (the normal testicular volume is 20 mL, while 50% of fragile X patients had testicular volumes of 30-50 mL), and large ears and FXS, fragile X syndrome; RTT, Rett syndrome; PWs, Prader-Willi syndrome; DS, Down syndrome; AS, Angleman syndrome; SZ, schizophrenia;
AD, Alzheimer disease.
other facial features. This syndrome is a result of the inactivation or dysfunction of FMR1 (fragile X mental retardation gene 1). 81 In most patients, the FMR1 gene is silenced by the expansion of an unstable triplet CGG repeat motif in the 5′UTR (untranslated region) that occurs in the maternal germ line. The number of CGG repeats is 5-45 in the general population. Genes with 45-200 repeats are referred to as premutation, and often experience a CGG repeat expansion mutation that gives rise to a full mutation (>200 repeats) in the offspring. 82, 83 An FMR1 gene containing more than 200 repeats is transcriptionally silenced by hypermethylation of the entire promoter region and flanking areas, resulting in decreased FMRP levels in the brain. 84, 85 There is much evidence indicating that the etiology of fragile X syndrome is affected by lncRNAs. FMR4 and FMR1-AS1, an antisense lncRNA that originates at the FMR1 gene locus and overlaps the CGG repeats region, are also silenced in fragile X syndrome patients but upregulated in premutation carriers. 86, 87 Loss-of-function and gain-of-function experiments have shown that FMR4 regulates cell cycle, proliferation and apoptosis. In addition, when FMR4 is knocked down or overexpressed in HEK293T cells, genomewide changes in gene expression occur. In differentiating human neural precursor cells, FMR4 expression is developmentally regulated in opposition to expression of both FMR1 and MBD4. 88 These data indicate that FMR4 is a regulator of gene expression through trans-activity, independent of FMR1. Furthermore, the expression of FMR4, FMR5, and FMR6 was found to be detectable in the majority of patient leukocyte RNA samples, suggesting that it may be feasible to use these lncRNAs as biomarkers for fragile X syndrome.
| LncRNAs and Down syndrome
Down syndrome (DS), the leading genetic cause of intellectual disabilities, is a common disorder caused by trisomy 21. Most DS patients also face multiple other health issues, such as congenital heart defects and hematopoietic disorders. 89, 90 X chromosome inactivation (XCI) is essential in female mammals, and nature has evolved a mechanism to compensate for the difference in number of X-linked gene copies between females and males. 91 XIST(X-inactive specific transcript) is a conserved lncRNA that is produced exclusively from the inactive X chromosome and "paints" the interphase chromosome structure.
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XIST induces numerous heterochromatin modifications and architectural changes and then recruits polycomb-group protein to transcriptionally silence the inactive X chromosome. [93] [94] [95] A notable recent report from Jiang and coworkers described the use of genome editing to control the expression of XIST. These researchers' method successfully silenced one copy of chromosome 21 in iPSCs derived from patients with DS, 96 resulting in improved deficiencies in proliferation and neural rosette formation. Importantly, this successful trisomy silencing in vitro overcomes a key step toward potential development of "chromosome therapy." 96 A study conducted by Celine and colleagues showed that the lncRNA XACT is expressed from and "coats" the active X chromosome in human pluripotent cells. 97 XIST and
XACT display a common function of lncRNAs by inducing chromatin remodeling and histone modification to regulate the transcription of multiple genes. In addition, nonprotein-coding RNA, repressor of NFAT (NRON), which is a lncRNA that mediates shuttling of the NFAT transcription factor between the cytoplasm and the nucleus, may also be involved in DS. 98 In animal models, deregulation of the DSCR1
and DYRK1A genes, which act synergistically to prevent nuclear occupancy of NFATc transcription factors, leads to reduced NFATc activity and contributes to many features of DS. These data suggest a potential link between NRON activity and DS pathophysiology. 
| LncRNAs, Angelman syndrome, and PraderWilli syndrome
Angelman syndrome (AS) is a neurodevelopmental disorder characterized by severe intellectual or developmental disability, sleep disturbance, seizures, jerky movements and an abnormal demeanor.
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The loss of maternal genetic material at the 15q11.2-13 locus results in AS. 107 The dosage of an imprinted gene or genes within the duplicated region underlies the autism risk in these individuals. Ubiquitin protein ligase E3A (UBE3A) is the only gene within the 15q11-13 duplicated segment, and a disruption in the UBE3A gene is thought to be causative for AS. 108 The lncRNA UBE3A-ATS, which can regulate the expression of UBE3A, is transcribed antisense to UBE3A, 109, 110 and high expression of UBE3A-ATS is detected in AS patients and mouse models. 111, 112 Additionally, many studies have demonstrated that reduction of UBE3A-ATS levels and sustained unsilencing of paternal UBE3A may be a feasible therapy for AS. 113, 114 However, some contrary results showed that unsilencing of UB3EA may also occur when UB3E-ATS is not present, suggesting that the regulation of UB3EA is more complex and is not limited to silencing by UB3E-ATS. 115, 116 Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, developmental delays, intellectual disability and behavioral issues, including ASDs. 117 PWS is caused by the deletion or lack of expression of genes in the15q11.2-q13 region of the paternally inherited chromosome. In most PWS patients, approximately 20 paternally inherited genes are missing. 118, 119 The lncRNA 116HG has also been reported to participate in the development of PWS. 116HG is a subnuclear RNA that copurifies with the transcriptional activator RBBP5
and an active metabolic gene, remains tethered to the site of its transcription and increases in size in postnatal neurons and during sleep.
A mouse model lacking 116HG exhibits increased energy expenditure corresponding to the dysregulation of diurnally expressed mammalian target of rapamycin (mTOR) and the circadian genes Clock, cryptochrome circadian clock1 (Cry1) and period circadian clock 2 (Per2). and function. However, research on lncRNAs, especially in CNS development and neurological disorders, is still in its initial stages. 138 We suggest that productive directions for future studies may include: (i)
determining the novel and higher order functions that are modulated by lncRNA-mediated mechanisms; (ii) elucidating the specific spatial and temporal expression patterns of lncRNAs and fully illustrating the dynamics of lncRNAs in the development of the CNS system and in neurological disorders; and (iii) studying how lncRNAs modulate pathogenetic events in neurodevelopmental disorders. Additionally, lncRNA research should not be limited to animal or cellular models. 139 More insight into their roles in ASD and other neurodevelopmental disorders might require the incorporation of epidemiological studies carried out on patients, as well as improvements in bioinformatics,
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which will help in understanding the function of those lncRNAs that have not been well characterized.
